Bispecific antibodies and autologous chimeric antigen receptor T?cell therapies for treatment of hematological malignancies.
Bispecific antibodies and autologous chimeric antigen receptor T?cell therapies for treatment of hematological malignancies. Mol Ther. 2024 May 31.